LAS VEGAS, May 8, 2017 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) announces the retirement and resignation, effective May 8, 2017, of its founder, Chairman and Chief Innovation Officer, Craig Ellins.
Mr. Ellins is the brilliant visionary behind the company's focus on pharmaceutical grade, consistent and efficacious medicines as well as much of its proprietary technology designed to produce and enhance those medicines. Principal among these is the groundbreaking GB tissue propagation technique that allows for identical plants to be cultivated, as opposed to the traditional methods of generational growing – where one plant is descended from its progenitor.
John Poss, who replaced Mr. Ellins as CEO last year, now also serves as Chairman of the Board.
Mr. Poss said: "We are all very disappointed to see Craig retire. His brilliance and guidance have steered this company to this major inflection point---where we are now positioned to become the Biopharma company of the future. The entire GB Sciences family will miss him and we wish him all the best."
Mr. Ellins states: "Of course it's difficult to leave this wonderful place, but I am very gratified that John Poss and the excellent team he has assembled have done such a wonderful job; thanks to them, I retire knowing that the seed I planted will blossom in the hands of some very talented managers and scientists."
About GB Sciences, Inc.
GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://growblox.com.
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
Liz Bianco Publicity Director, email@example.com, http://growblox.com
Investors: John Poss, firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/gb-sciences-revered-founder-craig-ellins-retires-300453801.html
SOURCE GB Sciences, Inc.